Biopharmaceutical manufacturer, Rentschler Biotechnologie has announced that it will be increasing its manufacturing capacity for the second time within a year.
Rentschler
The company will be opening a new facility with a capacity of two times 3,000 litres at its site in Laupheim. The Twin system of two stainless steel bioreactors is intended for the manufacturing of cell culture-derived proteins and is directly connected to equipment for protein purification.
The increase in capacity comes from a growing demand for biopharmaceuticals. The Twin system will aid in the development of drugs that can be used for example in the treatment of cancer and inflammatory diseases.
Rentschler’s growth means that the company will be able to create around 200 new jobs.
Dr. Frank Mathias, chief executive officer of Rentschler Biotechnologie, commented ”An increase in sales of over 30% in the past two years has enabled us to make this significant investment. We have already received manufacturing orders for the new facility, extending into 2018. Increasingly, our growth is being driven by international business, with more and more orders coming from abroad, particularly the United States."